drugset
drugset / Trial / NCT04213937

Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer

NCT04213937 ↗

Phase 2 Unknown 386 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with topotecan as second-line treatment for patients with extensive stage small cell lung cancer.

Timeline

Start
2020-01-31
Primary completion
2021-07-31
Completion
2022-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 125 mg/m2 Intravenous
Comparator Topotecan Small molecule 1.25 mg/m2 Intravenous

Indications

small cell lung carcinoma